A fragment-based design approach identifies reversible inhibitors targeting human protease complement factor D (FD), which is required for amplification of complement C3 signaling. FD inhibitors act as systemic regulators of complement activation in vivo.
- Jürgen Maibaum
- Sha-Mei Liao
- Karen Anderson
